Mar 6, 2024 7:30am EST Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
Feb 13, 2024 4:05pm EST Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update